Galimedix, Inc. | Finanzwire

Basculer en Français

11036	Companies
241881	Keywords
170270	Articles
130193	Press releases

Home
Companies
Galimedix, Inc.

BRIEF

published on 09/21/2026 at 13:05, 1 hour 4 minutes ago

Galimedix Forms Advisory Board to Guide Alzheimer's Drug Development

Advisory Board Clinical Trials Drug Development Alzheimer's Disease GAL-101
PRESS RELEASE

published on 09/21/2026 at 13:00, 1 hour 9 minutes ago

Galimedix establishes Scientific Advisory Board for Alzheimer’s disease to guide development of novel oral drug candidate, GAL-101
Galimedix establishes a Scientific Advisory Board for Alzheimer's disease to guide the development of GAL-101, a novel oral drug candidate, with global experts providing expertise in Phase 2 clinical-stage biotechnology

Scientific Advisory Board Clinical Development Alzheimer's Disease GAL-101 Galimedix
BRIEF

published on 09/11/2026 at 11:35, 10 days 2 hours ago

Galimedix Therapeutics Presents Phase 2 Data at EURETINA Congress

Galimedix Therapeutics Geographic Atrophy EDREAM Study EURETINA Congress Microperimetry
PRESS RELEASE

published on 09/11/2026 at 11:30, 10 days 2 hours ago

Galimedix Therapeutics to present functional feasibility data from Phase 2 eDREAM study in geographic atrophy at 26th EURETINA Congress
Galimedix Therapeutics to present functional feasibility data from Phase 2 eDREAM study in geographic atrophy at 26th EURETINA Congress on October 1-4, 2026 in Vienna, Austria

Galimedix Therapeutics Phase 2 Geographic Atrophy EDREAM Study EURETINA Congress
BRIEF

published on 03/20/2026 at 08:05, 6 months 1 day ago

Galimedix Unveils Promising Alzheimer’s Prodrug at AD/PD™ 2026

Galimedix Therapeutics Pharmacokinetic Profile Alzheimer’s Treatment Neuroprotective Therapy Oral Prodrug
PRESS RELEASE

published on 03/20/2026 at 08:00, 6 months 1 day ago

Galimedix Therapeutics presents strong pharmacokinetic profile of next-generation oral Alzheimer’s candidate at AD/PD™ 2026
Galimedix Therapeutics presents strong pharmacokinetic profile of next-generation oral Alzheimer's candidate at AD/PD™ 2026, demonstrating improved absorption and systemic exposure for patient-friendly dosing

Alzheimer's Disease Galimedix Therapeutics Pharmacokinetic Profile Oral Alzheimer's Candidate AD/PD™ 2026
BRIEF

published on 03/12/2026 at 13:05, 6 months 9 days ago

Galimedix Therapeutics Secures Milestone Payment in Partnership with Théa

Galimedix Therapeutics Théa Open Innovation GAL-101 Trials Ophthalmology Partnership Alzheimer's Advancement
PRESS RELEASE

published on 03/12/2026 at 13:00, 6 months 9 days ago

Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation
Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation, advancing oral therapy for eye diseases and Alzheimer’s

Phase 1 Trial Alzheimer's Disease Galimedix Therapeutics Milestone Payment Ophthalmology Partnership
BRIEF

published on 03/05/2026 at 14:05, 6 months 16 days ago

Galimedix Therapeutics to Showcase New Amyloid Beta Modulator at AD/PD 2026

Neurodegenerative Disorders Galimedix Therapeutics Pharmacokinetics Amyloid Beta AD/PD 2026 Conference
PRESS RELEASE

published on 03/05/2026 at 14:00, 6 months 16 days ago

Galimedix Therapeutics to present promising pre-clinical data with next generation oral amyloid beta aggregation modulator at AD/PD™ 2026 Conference
Galimedix Therapeutics to present pre-clinical data on new oral amyloid beta modulator at AD/PD™ 2026 Conference, discussing GAL-201 prodrugs and improved pharmacokinetics

Galimedix Therapeutics Pre-clinical Data Pharmacokinetic Profile Oral Amyloid Beta Modulator AD/PD™ 2026 Conference

1 2 ... 4

Accesswire

Published on 09/21/2026 at 13:45, 24 minutes ago

Nine Mile Metals DDH WD-26-11 Intersects 2 High Grade VMS Zones Over 27.6M Including 3.08% CU-EQ Over 10.70M, 3.27% CU-EQ Over 9.30M and 4.30% CU-EQ Over 5.0M
Published on 09/21/2026 at 13:30, 39 minutes ago

AI/ML Innovations Launches Quantum Soma Initiative with Dynex Quantum Technologies for Contactless Quantum Biosensing Platform
Published on 09/19/2026 at 00:55, 2 days 13 hours ago

Gossan Resources Announces Changes to Board and Management
Published on 09/18/2026 at 23:50, 2 days 14 hours ago

Mako Mining Announces Equity Incentive Grants
Published on 09/18/2026 at 22:00, 2 days 16 hours ago

Silver Tiger Announces Results of Annual and Special Meeting

View all ACCESSWIRE

EQS Group

Published on 09/21/2026 at 13:50, 19 minutes ago

Eurobattery Minerals’ Mentor Agreement terminated
Published on 09/21/2026 at 13:35, 34 minutes ago

DeFi Technologies' Subsidiary Valour Launches Valour Funds SPC, a New Business Line, and Introduces Its First Hedge Fund, Smart Crypto Fund SP, Powered by Neuronomics' Proprietary AI Strategy
Published on 09/21/2026 at 13:33, 35 minutes ago

EQS-Adhoc: DF Deutsche Forfait AG: Forecast revised upwards following the release of preliminary half-year results
Published on 09/21/2026 at 13:25, 44 minutes ago

Eurobattery Minerals’ Chairman resigns from the Board
Published on 09/21/2026 at 13:15, 54 minutes ago

Original-Research: MPH Health Care AG (von First Berlin Equity Research GmbH): Kaufen

Les Echos

Published on 09/21/2026 at 07:00, 7 hours 9 minutes ago

Peugeot Invest takes a stake in Mérieux NutriSciences
Published on 09/18/2026 at 18:34, 2 days 19 hours ago

Disclosure of transactions in own shares from September 14 to September 18, 2026
Published on 09/18/2026 at 17:45, 2 days 20 hours ago

Press Release_Carrefour Bond_September 2026
Published on 09/18/2026 at 17:45, 2 days 20 hours ago

Share buyback for cancellation
Published on 09/17/2026 at 17:40, 3 days 20 hours ago

Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany

View all LES ECHOS COMFI WIRE